While ACE inhibition may counteract these effects, some clinical studies have reported short-term cognitive benefits from ACEIs in early Alzheimer’s cohorts, underscoring the need for the context-specific evaluation of RAAS modulation in neurodegenerative disease management [113,114,115]. Here, ACE is linked to neurodegenerative disease.